Research and Development
Biota is focused on discovery, development and commercialization on the discovery and development of innovative anti-infective products to prevent and treat a number of serious and potentially life-threatening viral and bacterial infectious diseases. Our small molecule pipeline comprises antiviral programs in influenza, respiratory syncytial virus (RSV), human rhinovirus (HRV), hepatitis C (HCV), as well a new class of antibiotics to treat hospital-acquired and community-associated infections.
The company has a wealth of experience in medicinal chemistry, virology, microbiology, structural biology, drug characterization and non-clinical/clinical development. Our infrastructure includes state of the art, small molecule drug discovery laboratories, including synthetic chemistry suites, analytical chemistry laboratories, nuclear magnetic resonance (NMR), and physical containment level 2 laboratories plus physical containment level 3 laboratories. These laboratories are ideally suited to medicinal chemistry and are appropriately configured to permit work with infectious diseases as well as biochemistry, molecular biology and other associated disciplines.